Clinical Trial Update: PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

The PROCLAIM-CX-072 Phase 1/2 trial evaluating CX-072 for solid tumors and lymphomas has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• CX-072

Snippet

Sponsor: CytomX Therapeutics | Conditions: Solid Tumor, Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-17